{"id":152222,"date":"2025-04-27T17:13:11","date_gmt":"2025-04-27T17:13:11","guid":{"rendered":"https:\/\/websitedesigns.com.au\/elankanew\/?p=152222"},"modified":"2025-04-27T17:18:35","modified_gmt":"2025-04-27T17:18:35","slug":"advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake","status":"publish","type":"post","link":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/","title":{"rendered":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake"},"content":{"rendered":"<h2 style=\"text-align: center;\"><span style=\"color: #008080;\"><strong>Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake<\/strong><\/span><\/h2>\n<p><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-146797 size-thumbnail\" src=\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2024\/12\/Dr-Harold-Gunatillake-5-e1735136405289-150x150.png\" alt=\"Dr Harold Gunatillake\" width=\"150\" height=\"150\" \/><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><em>Non-Alcoholic Fatty Liver Disease (NAFLD) impacts<\/em><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><em>approximately<\/em> <em>25%<\/em> <em>of the global population, rendering it a substantial public health issue. Initiatives aimed at\u00a0 <\/em><\/span><span style=\"font-size: 16px; color: #000000;\"><em>enhancing screening <\/em><em>and early detection are of paramount importance, particularly in areas with elevated rates of obesity and diabetes.<\/em><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Exploring the Latest Discoveries and Treatments<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Nonalcoholic fatty liver disease (NAFLD) has emerged as one of the most prevalent chronic liver conditions globally, affecting millions of individuals. Its increasing prevalence is closely<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">correlated with the rising rates of obesity, type 2 diabetes, and metabolic syndrome. As researchers persist in elucidating the complexities of this disease, significant advancements have been achieved in comprehending its pathophysiology, diagnostic methodologies, and therapeutic strategies.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">About 100 million people (about 25%) in the United States are estimated to have Non-alcoholic Fatty Liver Disease (now called NAFLD).<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">The incidence of NAFLD is high among Sri Lankans. Available evidence suggests that NAFLD is the most common chronic liver disease in the country. In an extensive hospital-based study carried out recently, cryptogenic cirrhosis and alcoholic liver disease were found to be the two predominant etiological factors for cirrhosis in Sri Lanka.<\/span><\/p>\n<h1 style=\"text-align: justify;\"><strong><span style=\"font-size: 16px; color: #000000;\">Understanding NAFLD<\/span><\/strong><\/h1>\n<p style=\"text-align: justify;\"><strong><span style=\"font-size: 16px; color: #000000;\">What is NAFLD?<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Liver cells have a normal amount of fat deposits stored as triglycerides. This condition, known as fatty liver disease or hepatic steatosis, occurs when excess fat builds up in the liver. While a small amount of fat is typical in the liver, excessive accumulation can lead to various complications, including inflammation (steatohepatitis) and potentially cirrhosis.<\/span><\/p>\n<p><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-152223 aligncenter\" src=\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver-e1745773467206.jpg\" alt=\"liver\" width=\"600\" height=\"178\" \/><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">NAFLD is characterised by excessive fat accumulation in the liver, unrelated to alcohol consumption. It ranges from simple hepatic steatosis (fat buildup) to nonalcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, or even hepatocellular carcinoma.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Risk Factors<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">The primary risk factors for NAFLD include obesity, insulin resistance, type 2 diabetes, high cholesterol, and hypertension. Genetic predispositions also play a role, with specific gene variants such as PNPLA3 and TM6SF2 linked to increased susceptibility.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Obesity is a rampant issue among Sri Lankans, commonly characterised by the presence of \u2018potbellies,\u2019 in which adipose tissue is predominantly concentrated within the abdominal cavity surrounding several vital organs; this type of fat is commonly referred to as visceral fat.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Although it is not accurate to assert that nearly all individuals with uncontrolled diabetes develop non-alcoholic fatty liver disease (NAFLD), the incidence of NAFLD among those with type 2 diabetes (T2D) is notably elevated, with estimates ranging from 55% to 70%. This indicates that a considerable majority of individuals diagnosed with T2D are likely to develop NAFLD, particularly those who are also classified as overweight or obese.<\/span><\/p>\n<h1 style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Recent Developments in Diagnosis<\/strong><\/span><\/h1>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Enhanced Imaging Techniques<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Traditional methods of diagnosing NAFLD include ultrasound and liver biopsy. However, newer imaging technologies have gained prominence, such as transient elastography (FibroScan) and magnetic resonance imaging-proton density fat fraction (MRI- PDFF). These methods provide non-invasive and accurate assessments of liver fat content and fibrosis.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Biomarker Discovery<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Recent research has focused on the identification of biomarkers for NAFLD and NASH. Biomarkers such as cytokeratin-18 (CK-18) and adiponectin levels are showing promise for assessing disease severity without the need for invasive procedures.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">In individuals diagnosed with obesity and non-alcoholic steatohepatitis (NASH), heightened plasma CK-18 levels (exceeding 150 U\/L) correlate with diminished adiponectin levels, thereby suggesting a connection between hepatic cellular damage and decreased adiponectin, a hormone pivotal for metabolic well-being. This correlation may signify a metabolic phenotype associated with obesity, wherein elevated CK-18 levels denote mild hepatic injury and metabolic complications.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Liver function tests, specifically blood tests assessing liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are frequently utilised to assist in the diagnosis of non-alcoholic fatty liver disease (NAFLD). Increased concentrations of these enzymes may signify liver inflammation or damage, indicating the potential presence of NAFLD.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Liver function tests are blood tests that help find the cause of your symptoms and monitor liver disease or damage. The tests measure the levels of certain enzymes and proteins in your blood as mentioned above..<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Some of these tests measure how well the liver performs its regular functions of producing protein and clearing bilirubin, a blood waste product. Other liver function tests measure enzymes that liver cells release in response to damage or disease.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Irregular liver function test results don&#8217;t always mean liver disease. A health care team member will typically explain your results and what they mean.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Nevertheless, liver function tests are not always definitive and are typically employed with imaging examinations, such as ultrasound or magnetic resonance imaging (MRI), to corroborate the diagnosis.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Magnetic resonance elastography combines MRI imaging with sound waves to create a visual map, or elastogram, showing the stiffness of body tissues.<\/span><\/p>\n<p><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-152224 aligncenter\" src=\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver-2-e1745773595744.jpg\" alt=\"liver\" width=\"600\" height=\"261\" \/><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\"><strong>Advancements in Treatment<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\"><strong>Pharmacological Innovations<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\">Currently, several pharmacological agents are undergoing clinical trials aimed at addressing various aspects of the pathogenesis associated with non-alcoholic fatty liver disease (NAFLD):<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\">** Elafibranor **: This compound functions as a dual agonist of peroxisome proliferator-activated receptors (PPAR), demonstrating efficacy in enhancing hepatic health by mitigating inflammation and fibrosis.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\">** Obeticholic Acid (OCA) **: As a farnesoid X receptor (FXR) agonist, OCA regulates bile acid synthesis and reduces hepatic fat accumulation.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\">** Semaglutide **: Initially utilised as a treatment for type 2 diabetes, semaglutide has shown promising potential in reducing liver fat and enhancing metabolic parameters.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\"><strong>Lifestyle Interventions<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px;\">While pharmacological treatments continue to evolve, lifestyle modifications persist as the cornerstone of managing Non- Alcoholic Fatty Liver Disease (NAFLD). Weight reduction achieved through dietary changes, enhanced physical activity, and behavioural interventions has been demonstrated to improve liver function and decrease fat accumulation significantly.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Gut Microbiome Research<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Recent studies underscore the significance of the gut microbiome in the progression of Non-Alcoholic Fatty Liver Disease (NAFLD).<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Modulating the microbiome through probiotics, prebiotics, or faecal microbiota transplantation (FMT) is currently being investigated as a promising therapeutic approach.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Therapeutic effects of polysaccharides on NAFLD<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">First, polysaccharides need to be defined.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Polysaccharides are a significant class of biomolecules. They are long chains of carbohydrate molecules composed of several smaller monosaccharides. These complex biomacromolecules are an essential energy source in animal cells and a structural component of plant cells.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Polysaccharides, acting as prebiotics, can potentially help manage non-alcoholic fatty liver disease (NAFLD) by modulating the gut-liver axis. They do this by influencing gut microbiota composition and function, improving intestinal barrier integrity, and reducing the translocation of harmful substances like lipopolysaccharide (LPS). This helps to reduce inflammation and improve lipid metabolism in the liver.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Modulating Gut Microbiota:<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Polysaccharides can alter the composition and diversity of gut bacteria, potentially restoring a healthier balance.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">They can increase the abundance of beneficial bacteria that produce short-chain fatty acids (SCFAS) essential for energy and signalling.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Polysaccharides regulate the gut microbiota and can influence the production of various metabolites, including LPS and bile acids (BAS), which can directly impact liver health.<\/span><\/p>\n<ol style=\"text-align: justify;\" start=\"2\">\n<li><span style=\"font-size: 16px; color: #000000;\">Improving Intestinal Barrier Function:<\/span><\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Polysaccharides can strengthen the intestinal barrier, reducing the permeability of harmful substances like LPS into the bloodstream.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">This helps to prevent liver inflammation, which is a key factor in the development and progression of NAFLD.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">A polysaccharide from jackfruit pulp has been found to improve liver function in a high-fat diet.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Global Implications and Future Directions<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"font-size: 16px; color: #000000;\">Personalised Medicine<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Integrating genetic, metabolic, and microbiome data facilitates the advancement of personalised medicine strategies in treating Non-Alcoholic Fatty Liver Disease (NAFLD). Customised interventions derived from individual risk profiles and disease mechanisms present promising opportunities for enhanced management effectiveness.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>International Collaboration<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Organisations such as the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) are spearheading collaborative initiatives to standardise diagnostic criteria, promote research, and formulate global strategies for the prevention and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\"><strong>Conclusion<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">Recent advancements in the research on Non-Alcoholic Fatty Liver Disease (NAFLD) underscore the intricate nature of this condition and emphasise the necessity for multidisciplinary approaches. Significant progress has been noted in the areas of imaging, biomarker discovery, pharmacological treatments, and gut microbiome modulation, so the prospects for managing NAFLD appear optimistic. Continued investment in research initiatives, awareness campaigns, and international collaboration will be crucial in addressing this escalating health concern.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">This vibrant field of study persists in its evolution, offering renewed hope for the millions of individuals impacted by NAFLD and layingbthe groundwork for innovative treatments that target the underlying causes of the disease.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">This topic can be a bit complicated, and you might find it helpful to read through it a few times to grasp its essence fully. I hope you find it useful, primarily as you work towards recovering from liver issues.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 16px; color: #000000;\">End<\/span><\/p>\n<p><a href=\"https:\/\/economictimes.indiatimes.com\/?back=1\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-152225 size-full\" src=\"https:\/\/img.etimg.com\/photo\/msid-109407038\/liver-healthy-habits-to-follow.jpg\" alt=\"\" width=\"600\" height=\"400\" \/><\/a><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 16px; color: #000000;\"><em>Image Source :\u00a0<a style=\"color: #000000;\" href=\"https:\/\/economictimes.indiatimes.com\/?back=1\" target=\"_blank\" rel=\"noopener\">economictimes<\/a><\/em><\/span><\/p>\n<div style=\"text-align: center;\"><span style=\"color: #800000;\"><em><a style=\"color: #800000;\" href=\"https:\/\/websitedesigns.com.au\/elankanew\/elanka-newsletter-sign-up\/\" target=\"_blank\" rel=\"noopener\"><strong>Click here to receive your free copy of the eLanka Newsletter twice a week delivered directly\u00a0to\u00a0your\u00a0inbox!<\/strong><\/a><\/em><\/span><\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake Non-Alcoholic Fatty Liver Disease (NAFLD) impacts approximately 25% of the global population, rendering it a substantial public health issue. Initiatives aimed at\u00a0 enhancing screening and early detection are of paramount importance, particularly in areas with elevated rates of obesity and diabetes. Exploring [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":152225,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"aside","meta":{"footnotes":""},"categories":[20,1103],"tags":[79261,79258,79260,79257,79256,43154,79259,79262],"class_list":{"0":"post-152222","1":"post","2":"type-post","3":"status-publish","4":"format-aside","5":"has-post-thumbnail","7":"category-articles","8":"category-dr-harold-gunatillake","9":"tag-gut-microbiome-and-nafld","10":"tag-latest-discoveries-in-nafld","11":"tag-nafld-and-obesity-link","12":"tag-nafld-diagnosis-and-treatment","13":"tag-nafld-research-2025","14":"tag-non-alcoholic-fatty-liver-disease","15":"tag-nonalcoholic-steatohepatitis-nash","16":"tag-obesity-and-liver-disease","17":"post_format-post-format-aside"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.7.1 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Non-alcoholic Fatty Liver Disease<\/title>\n<meta name=\"description\" content=\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold Gunatillake\" \/>\n<meta property=\"og:description\" content=\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\" \/>\n<meta property=\"og:site_name\" content=\"eLanka\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/eLanka.com.au\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-27T17:13:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-27T17:18:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"eLanka admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"eLanka admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\"},\"author\":{\"name\":\"eLanka admin\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/f6e635b74ab35ef88a68a9973cacc5bd\"},\"headline\":\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake\",\"datePublished\":\"2025-04-27T17:13:11+00:00\",\"dateModified\":\"2025-04-27T17:18:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\"},\"wordCount\":1465,\"publisher\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#organization\"},\"image\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png\",\"keywords\":[\"Gut microbiome and NAFLD\",\"Latest discoveries in NAFLD\",\"NAFLD and obesity link\",\"NAFLD diagnosis and treatment\",\"NAFLD research 2025\",\"Non-alcoholic fatty liver disease\",\"Nonalcoholic steatohepatitis (NASH)\",\"Obesity and liver disease\"],\"articleSection\":[\"Articles\",\"Dr harold Gunatillake\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\",\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\",\"name\":\"Non-alcoholic Fatty Liver Disease\",\"isPartOf\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png\",\"datePublished\":\"2025-04-27T17:13:11+00:00\",\"dateModified\":\"2025-04-27T17:18:35+00:00\",\"description\":\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)\",\"breadcrumb\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage\",\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png\",\"contentUrl\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/websitedesigns.com.au\/elankanew\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Articles\",\"item\":\"https:\/\/websitedesigns.com.au\/elankanew\/category\/articles\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#website\",\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/\",\"name\":\"eLanka\",\"description\":\"eLanka - Sri lanka events in Australia\",\"publisher\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/websitedesigns.com.au\/elankanew\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#organization\",\"name\":\"eLanka\",\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2020\/03\/elanka-logo.jpg\",\"contentUrl\":\"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2020\/03\/elanka-logo.jpg\",\"width\":192,\"height\":82,\"caption\":\"eLanka\"},\"image\":{\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/eLanka.com.au\/\",\"https:\/\/www.linkedin.com\/in\/elanka\/\",\"https:\/\/www.youtube.com\/user\/SriLankanDownUnder\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/f6e635b74ab35ef88a68a9973cacc5bd\",\"name\":\"eLanka admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2e0d346a7f97b80e861cdeafe7b7de523b59f5060666f1a5da8369457bf9b6c3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2e0d346a7f97b80e861cdeafe7b7de523b59f5060666f1a5da8369457bf9b6c3?s=96&d=mm&r=g\",\"caption\":\"eLanka admin\"},\"sameAs\":[\"https:\/\/websitedesigns.com.au\/elankanew\"],\"url\":\"https:\/\/websitedesigns.com.au\/elankanew\/author\/elanka\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Non-alcoholic Fatty Liver Disease","description":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold Gunatillake","og_description":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)","og_url":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/","og_site_name":"eLanka","article_publisher":"https:\/\/www.facebook.com\/eLanka.com.au\/","article_published_time":"2025-04-27T17:13:11+00:00","article_modified_time":"2025-04-27T17:18:35+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png","type":"image\/png"}],"author":"eLanka admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"eLanka admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#article","isPartOf":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/"},"author":{"name":"eLanka admin","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/f6e635b74ab35ef88a68a9973cacc5bd"},"headline":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake","datePublished":"2025-04-27T17:13:11+00:00","dateModified":"2025-04-27T17:18:35+00:00","mainEntityOfPage":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/"},"wordCount":1465,"publisher":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/#organization"},"image":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage"},"thumbnailUrl":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png","keywords":["Gut microbiome and NAFLD","Latest discoveries in NAFLD","NAFLD and obesity link","NAFLD diagnosis and treatment","NAFLD research 2025","Non-alcoholic fatty liver disease","Nonalcoholic steatohepatitis (NASH)","Obesity and liver disease"],"articleSection":["Articles","Dr harold Gunatillake"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/","url":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/","name":"Non-alcoholic Fatty Liver Disease","isPartOf":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/#website"},"primaryImageOfPage":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage"},"image":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage"},"thumbnailUrl":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png","datePublished":"2025-04-27T17:13:11+00:00","dateModified":"2025-04-27T17:18:35+00:00","description":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research - By Dr Harold GunatillakeNon-Alcoholic Fatty Liver Disease (NAFLD)","breadcrumb":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#primaryimage","url":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png","contentUrl":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2025\/04\/liver.png","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/websitedesigns.com.au\/elankanew\/advancements-in-non-alcoholic-fatty-liver-disease-nafld-research-by-dr-harold-gunatillake\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/websitedesigns.com.au\/elankanew\/"},{"@type":"ListItem","position":2,"name":"Articles","item":"https:\/\/websitedesigns.com.au\/elankanew\/category\/articles\/"},{"@type":"ListItem","position":3,"name":"Advancements in Non-alcoholic Fatty Liver Disease (NAFLD) Research &#8211; By Dr Harold Gunatillake"}]},{"@type":"WebSite","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#website","url":"https:\/\/websitedesigns.com.au\/elankanew\/","name":"eLanka","description":"eLanka - Sri lanka events in Australia","publisher":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/websitedesigns.com.au\/elankanew\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#organization","name":"eLanka","url":"https:\/\/websitedesigns.com.au\/elankanew\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/logo\/image\/","url":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2020\/03\/elanka-logo.jpg","contentUrl":"https:\/\/websitedesigns.com.au\/elankanew\/wp-content\/uploads\/2020\/03\/elanka-logo.jpg","width":192,"height":82,"caption":"eLanka"},"image":{"@id":"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/eLanka.com.au\/","https:\/\/www.linkedin.com\/in\/elanka\/","https:\/\/www.youtube.com\/user\/SriLankanDownUnder"]},{"@type":"Person","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/f6e635b74ab35ef88a68a9973cacc5bd","name":"eLanka admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/websitedesigns.com.au\/elankanew\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2e0d346a7f97b80e861cdeafe7b7de523b59f5060666f1a5da8369457bf9b6c3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2e0d346a7f97b80e861cdeafe7b7de523b59f5060666f1a5da8369457bf9b6c3?s=96&d=mm&r=g","caption":"eLanka admin"},"sameAs":["https:\/\/websitedesigns.com.au\/elankanew"],"url":"https:\/\/websitedesigns.com.au\/elankanew\/author\/elanka\/"}]}},"_links":{"self":[{"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/posts\/152222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/comments?post=152222"}],"version-history":[{"count":3,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/posts\/152222\/revisions"}],"predecessor-version":[{"id":152232,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/posts\/152222\/revisions\/152232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/media\/152225"}],"wp:attachment":[{"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/media?parent=152222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/categories?post=152222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/websitedesigns.com.au\/elankanew\/wp-json\/wp\/v2\/tags?post=152222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}